

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/20		A1	(11) International Publication Number: WO 94/16690 (43) International Publication Date: 4 August 1994 (04.08.94)
(21) International Application Number: PCT/US93/11093 (22) International Filing Date: 16 November 1993 (16.11.93) (30) Priority Data: 08/007,413 22 January 1993 (22.01.93) US			(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365, Madison, WI 53707-7365 (US). (72) Inventors: COOK, Mark, E.; 313 South Segoe Road, Madison, WI 53705 (US). PARIZA, Michael, W.; 6913 Pilgrim Road, Madison, WI 53711 (US). (74) Agents: KRYSHAK, Thad, F. et al.; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).			

(54) Title: METHOD FOR INCREASING THE EFFICIENCY OF FEED CONVERSION IN ANIMALS

(57) Abstract

A method of enhancing weight gain and feed efficiency in an animal which comprises administering to the animal a safe and effective amount of a conjugated linoleic acid.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

METHOD FOR INCREASING THE EFFICIENCY OF
FEED CONVERSION IN ANIMALS

The present invention generally relates to animal nutrition. More particularly, it relates to a method of increasing the efficiency of feed conversion in an animal into body weight.

The efficiency of feed conversion into body weight varies significantly among different species of animals. Because feed is a relatively expensive cost factor in the production of food producing animals (50 to 70% of the cost of production), any improvement in the ability of the animal to convert feed into food products can directly improve the profitability of a food producer. For example, an increase in the efficiency of feed conversion in broilers that results in a 1% increase in body weight for the same amount of feed could alone result in savings of over 85 million dollars for the U.S. broiler industry. In addition, there would be millions of dollars of savings because of reduced mortality and a reduction in the days required before marketing the broilers.

There is a need for a method of improving the ability of healthy meat animals to more efficiently convert their feed to body weight or other edible products.

There also is a need for a safe and effective method for increasing the body weight of animals, including

-2-

humans, who for medical or other reasons can only consume a limited amount of food.

It is an object of the present invention to disclose a method of enhancing weight gain and feed efficiency in
5 an animal.

We have discovered a method of enhancing weight gain and feed efficiency in an animal which comprises administering to said animal a weight gain enhancing and feed efficiency enhancing amount of a conjugated linoleic acid (CLA) selected from 9,11-octadecadienoic acid; 10,12-octadecadienoic acid; and mixtures thereof.

It will be apparent to those skilled in the art that the forementioned objects and other advantages may be achieved by the practice of the present invention.

15 In a preferred embodiment of the method of the
present invention the safe and effective amount of the
conjugated linoleic acid, which is selected from 9,11-
octadecadienoic acid; 10,12-octadecadienoic acid and
mixtures thereof, is added to the feed of an animal in
20 which it is desired to enhance the efficiency of feed
conversion and enhance body weight. The amount of the
conjugated linoleic acid to be added to the animal's feed
will vary with the species and size of the animal.
However, since the conjugated linoleic acids are natural
25 food ingredients and relatively non-toxic, the amount
which can be administered is not critical as long as it
is enough to be effective.

The practice of the present invention is further illustrated by the examples which follow:

30 Example 1
Groups of one week old chicks were fed a standard control diet, or the diet supplemented with 0.5% CLA, or with 0.5% linoleic acid. Feed consumption and weight gain were closely monitored. After 1 week, the feed
35 conversion (grams of feed required to produce 1 gram increase in weight gain) were as follows: group fed

-3-

control diet, 1.55 grams feed; group fed diet containing 0.5% CLA, 1.42 grams feed; group fed diet containing 0.5% linoleic acid, 1.56 grams feed. After 2 weeks, the feed conversions were: control group, 1.57 grams feed; group 5 fed 0.5% CLA, 1.46 grams feed; group fed 0.5% linoleic acid, 1.53 grams feed. Clearly, when CLA was added to the diet, less feed was required to produce an equivalent weight gain. Hence, the CLA clearly improved the feed conversion efficiency of the animals.

10

Example 2

Four pens of 10 chicks were fed a standard poultry ration with 0.5% lard (controls) or with 0.5% CLA mixed daily (2 pens per treatment). When the chicks were 3 weeks of age, they were weighed and then injected with 15 endotoxin. As seen in Table 1 the chicks fed the unsupplemented diet failed to gain body weight over the next 24 hours, whereas the chicks fed CLA gained up to 10 grams ($p < .07$).

20

TABLE 1

<u>Treatment</u>	<u>Av. Initial Wt.</u>	<u>Av. Wt. 24h post endotoxin</u>	<u>Av. initial 24h</u>	<u>% with no gain or negative</u>
	<u>Wt.</u>	<u>endotoxin</u>	<u>24h</u>	<u>gain</u>
Control	311 ± 12	311 ± 12	0 ± 3	53
.5% CLA	305 ± 9	315 ± 9	10 ± 4	27

25

Example 3

Another group of chicks were fed a diet containing 0.5% CLA which was mixed with the feed daily. At 3 weeks of age the chicks were inoculated i.p. with 750 μ g E. Coli 055:B5 endotoxin to stimulate immunity or phosphate buffered saline (PBS) as a control. The control chicks injected with PBS gained 9 g over the following 24h period, and the CLA fed, PBS injected chicks gained 13.5 g. When chicks fed the control diet were injected with endotoxin, they lost 1.3 g of body weight over the 30 following 24h period. However, the CLA fed chicks even 35 following 24h period.

-4-

after endotoxin injection continued to gain an average of 6.6 g.

The results of the examples demonstrate that a lower proportion of chicks lose weight, within 24 hours of 5 being injected with endotoxin, when the chicks ingest feed which contains CLA. In fact, the results in Tables 2 and 3 show that not only do a fewer number of birds lose weight but that those birds that are fed CLA actually gain considerably more weight than the control 10 birds. In addition, in other studies the loss of body weight in rats fed CLA following stimulation was found to be only 50% of those not fed CLA.

TABLE 2

15 Effect of feeding different levels of CLA to chicks¹ on 24 hour body weight gain following endotoxin injection

<u>Diet</u>	<u>24 hr gain (g)</u>	<u>% neg. gain³</u>
Control ²	1.7	40%
0.3%	5.5	18%
1.0%	3.3	28%
20 <u>Total CLA</u>	<u>24 hr gain (g)</u>	<u>% neg. gain</u>
-	1.7	40%
+	4.4	23%

¹Chicks were fed CLA for 14 consecutive days prior to endotoxin injection.

25 ²Diet analysis revealed trace amounts of CLA in control diet. Contamination was most likely from pig lard which was used as the dietary fat source.

³The number of chicks with a negative weight gain during the 24 hour period immediately following endotoxin challenge.

-5-

TABLE 3

Effect of feeding CLA¹ to chicks for 3 or less days, or
for more than 3 or more days² prior to endotoxin
challenge on 24 hour body weight gain.

5	Time <u>fed CLA</u>	Gain 24 hr <u>post challenge</u>	% BW <u>change</u>	Feed consumed <u>per chick</u> ³
	>3 days	-0.95	-0.32	13.17 g
	≤3 days	-5.42	-2.08	9.56 g

¹Chicks were fed 0.5% CLA in their diets.

¹⁰ ²Greater than 3 days means up to 21 days.

³Feed consumed in the 24 hours post endotoxin challenge.

Increased feed intake in this experiment equates with mitigation of illness from endotoxin challenge.

Example 4

15 A group of seven rats was fed a semi-purified diet containing 5% corn oil and .5% stearic acid; a second group was fed the same diet with corn oil but also containing added free linoleic acid (0.5%). Three weeks later the animals were weighed. Four animals from each 20 group were inoculated with endotoxin (1 mg/kg body weight); the remaining three animals from each group were inoculated with PBS. Rats fed the control diet and injected with PBS gained 7.4 g. Rats fed the diet to which linoleic acid had been added, and injected with 25 PBS, gained 7.2 g. Rats fed control diet and injected with endotoxin lost 21.05 g. Rats fed diet to which linoleic acid had been added, and injected with endotoxin, lost only 11.4 g. These results are due to the conversion of added linoleic acid to CLA within the 30 body of rats.

-6-

Example 5

To demonstrate the unique ability of CLA to increase the efficiency of rabbits to convert feed into body weight, the rabbits were fed food supplemented with CLA, 5 linoleic acid, and oils. The amounts of the CLA, the linoleic acid and the oils administered and the results are shown in Tables 4 to 6.

TABLE 4

SEMI-SYNTETIC DIET WITH 12% COCONUT OIL AND 2% CORN OIL			
	#	Food Consumption (g)	Body Weight Gain (g)
	1	53	-60
15	2	48	-180
	3	29	-150
	4	59	-230
	5	42	-320
20		}	46g (average)}
	6	60	-150
	7	44	-330
	8	37	-100
	9	36	-210
25	10	47	-270
			-200g (average)

-7-

TABLE 5

**RABBITS #1-6 SWITCHED
TO SAME SEMI-SYNTHETIC
DIET SUPPLEMENTED
WITH 0.5% COCONUT OIL**

	#	Food Consumption (g)	Body Weight Gain (g)
	1	54	0
10	2	46	-100
	3	45	-140
		}	53g (average)}
	4	64	-120
15	5	51	-170
	6	54	-100

TABLE 6

**RABBITS #7-10 SWITCHED
TO SAME SEMI-SYNTHETIC
DIET SUPPLEMENTED
WITH 0.5% CLA**

	#	Food Consumption (g)	Body Weight Gain (g)
25	7	53	+30
	8	47	+30
		}	49g (average)}
	9	42	+50
30	10	55	+10

-8-

Example 6

Three groups of rabbits (4/group) were fed control chow diet, chow diet containing 1% CLA, or chow diet containing 1% linoleic acid. The animals were given 5 100 g of feed each day. During a 3-week period, the mean weight gain for these groups was as follows:

Rabbits fed control diet	35 g
Rabbits fed diet containing 1% CLA	132 g
Rabbits fed diet containing 1% linoleic acid . .	75 g

10 Clearly, the results show that CLA has a substantial positive effect on weight gain in these animals. The effect of CLA is greater than that observed with linoleic acid. During the 21-day time period, the CLA-fed rabbits ate 21 g CLA. Even if all of this CLA were retained as 15 body fat, it would not account for the observed weight gain relative to controls (132g - 35g = 97g).

Example 7

Three groups of 14 healthy chicks were fed a basal diet with 0 (control), .3, or 1% CLA. Pen feed 20 conversion was determined weekly for 3 weeks. During all periods, 0 to 1 weeks, 0 to 2 weeks, 0 to 3 weeks of age on the dietary treatments, chicks fed CLA had marked improvements in the grams of feed needed to generate a gram of body weight (Table 7). The results in Table 7 25 are similar to the results seen in rats, mice and rabbits.

TABLE 7

Feed intake (g)/Body weight gain (g)

	<u>Treatment</u>	<u>0-1 wk</u>	<u>0-2 wk</u>
30	control	2.53	2.62
	.3% CLA	2.38	2.40
	1% CLA	2.34	2.16

-9-

Example 8

Rats (7 per treatment) were individually caged and fed a diet containing .5% stearic acid, or .5% CLA for 4 weeks. Each week the amount (grams) of feed needed for 5 gain (grams) was determined. Rats fed CLA consistently had better feed conversion than rats fed stearic acid (Table 8).

TABLE 8

		Feed intake (g)/Body weight gain (g)			
10	<u>Treatment</u>	<u>Wk 1</u>	<u>Wk 2</u>	<u>Wk 3</u>	<u>Wk 4</u>
	.5% stearate	2.98	2.90	3.34	3.57
	.5% CLA	2.51	2.49	3.02	3.36

Example 9

Ten rats, individually caged, were fed a control 15 diet (.5% stearate) or a diet containing .5% CLA for 1 week, 2 weeks, 3 weeks, or 4 weeks. Feed intake/gain was calculated for each period rats were fed CLA or stearate. Table 9 shows that rats fed CLA for 2, 3, or 4 weeks had a marked improvement in the grams of feed needed for a 20 gram of gain.

TABLE 9

		Feed intake (g)/Body weight gain (g)			
	<u>Treatment</u>	<u>Wk 1*</u>	<u>Wk 2</u>	<u>Wk 3</u>	<u>Wk 4</u>
	.5% stearate	1.87	2.13	2.48	2.73
25	.5% CLA	1.85	1.58	2.11	2.64

*indicates the length of time the rats were fed CLA.

-10-

Example 10

Fourteen individually caged rats were assigned to each of 3 dietary treatments: Control (no CLA), .3% CLA, and 1% CLA. The amount of feed (grams) needed for each 5 gram of gain was determined each week for 2 weeks. Rats fed .3 or 1% CLA had a reduction in the grams of feed needed for each gram of gain (Table 10).

TABLE 10

Feed intake (g)/Body weight gain (g)

10	<u>% CLA</u>	<u>0-1 Wk</u>	<u>1-2 Wk</u>	<u>0-2 Wk</u>
	0	2.74	2.68	2.71
	.3	2.27	2.17	2.21
	1.0	1.89	2.20	2.05

Example 11

15 Three-week old mixed sexed mice (5 groups of 4 mice per dietary treatment) were fed a diet containing no fatty acid addition, .5% fish menhaden oil, or .5% CLA. After 15 days of feeding 2 groups of mice per dietary treatment were injected ip with 1 mg E. coli O55:B5 20 lipopolysaccharide (LPS) in HEPES buffer, 1 group of mice per dietary treatment was injected ip with mouse interleukin-1 in HEPES buffer, and 2 groups of mice per dietary treatment were injected ip with only HEPES buffer. The percent change in feed consumed of mice 25 injected with LPS or IL-1 relative to the HEPES injected mice within each dietary treatment was determined 24 hours after the injections. Table 11 shows that CLA-fed mice injected with LPS had less of a relative reduction in feed intake than mice fed fish oil or no fat inclusion. When the mice fed the various dietary 30 treatments were injected with IL-1, those mice fed the basal diet had a 20% relative reduction in feed intake, while those fed CLA had an actual 10% increase in relative feed intake. The fish oil fed mice had 35 intermediate intakes. These data suggest that CLA is

-11-

effective in preventing or reducing the negative effects immune stimulation has on feed intake.

TABLE 11

Consumption (24 hr) following immune stim.
5 (% gain relative to HEPES injection)

<u>Treatment</u>	<u>IL-1</u>	<u>LPS</u>
Basal	-20.0	-96.3
.5% fish oil	+ 4.5	-95.1
.5% CLA	+10.3	-27.5

10 The use of CLA in poultry feed improves the ability to convert feed, enhances growth and prevents weight loss in poultry. For broiler chickens alone, a decrease in feed/body weight of .01 could equal savings of \$22 million/yr to the broiler industry. The difference 15 between the conversion of the control and 1% CLA would thus be worth over \$1 billion/yr.

15 In another embodiment of the invention, linoleic acid is administered to an animal which can convert the linoleic acid into CLA or which modulates the level of 20 CLA in the body of an animal or a human. The linoleic acid is converted to CLA in the animal, probably by microorganisms in the animal's gastrointestinal system.

20 The method of the present invention may take other embodiments. For example, the CLA can be administered to 25 an animal in a pharmaceutical or veterinary composition, such as tablets, capsules, solutions or emulsions, containing a safe and effective dose of the CLA.

25 The animal feeds and pharmaceutical preparations for use in the method of the present invention are those 30 containing the active forms of the free conjugated linoleic acids (CLA), especially 9,11-octadecadienoic acid and 10,12-octadecadienoic acid or mixtures thereof in combination with a conventional animal feed (e.g.

-12-

poultry feed), human food supplement, or an approved pharmaceutical diluent.

The active forms of CLA include, in addition to the free acids the active isomers of CLA; non-toxic salts 5 thereof; active esters and other active chemical derivatives thereof; and mixtures thereof.

The free conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anticarcinogens. Since then, they have been found in 10 some processed cheese products. However, animal feeds containing CLA, or its non-toxic derivatives, such as the sodium and potassium salts, as an additive in combination with conventional animal feeds or human foods are believed to be novel.

15 The free acid forms of the CLA may be prepared by isomerizing linoleic acid. The non-toxic salts of the free CLA acids may be made by reacting the free acids with a non-toxic base. Natural CLA may also be prepared from linoleic acid by the action of an isomerase from a 20 harmless microorganism such as the Rumen bacterium Butyrivibrio fibrisolvens. Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA.

The CLA obtained by the practice of the described 25 methods of preparation contains one or more of the 9,11-octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers thereof. It may be free or bound chemically through ester linkages. The CLA is heat stable and can be used as is, or dried and powdered. The 30 CLA is readily converted into a non-toxic salt, such as the sodium or potassium salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9.

Theoretically, 8 possible geometric isomers of 9,11- 35 and 10,12-octadecadienoic acid (c9,c11; c9,t11; t9,c11; t9,t11; c10,c12; c10,t12; t10,c12 and t10,t12) would form

-13-

from the isomerization of c₉,c₁₂-octadecadienoic acid. As a result of the isomerization, only four isomers (c₉,c₁₁; c₉,t₁₁; t₁₀,c₁₂; and c₁₀,c₁₂) would be expected. However, of the four isomers, c₉,t₁₁- and t₁₀,c₁₂-
5 isomers are predominantly produced during the autoxidation or alkali-isomerization of c₉,c₁₂-linoleic acid due to the co-planar characteristics of 5 carbon atoms around a conjugated double-bond and spatial conflict of the resonance radical. The remaining two
10 c,c-isomers are minor contributors.

The relatively higher distribution of the t,t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the further stabilization of c₉,t₁₁- or t₁₀,c₁₂-geometric isomers, which is thermodynamically
15 preferred, during an extended processing time or long aging period. Additionally the t,t-isomer of 9,11- or 10,12-octadecadienoic acid that was predominantly formed during the isomerization of linoleic acid geometrical isomers (t₉,t₁₂-, c₉,t₁₂- and t₉,c₁₂-octadecadienoic
20 acid) may influence the final ratio of the isomers or the final CLA content in the samples.

Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and 10,12-, t₉,c₁₁- and c₁₁,t₁₂-octadecadienoic acids).
25 The 11,13-isomer might be produced as a minor product from c₉,c₁₂-octadecadienoic acid or from its isomeric forms during processing.

The exact amount of CLA to be administered, of course, depends upon the animal, the form of CLA
30 employed, the route of administration, and extent of the increase in body weight desired.

Generally, the amount employed of CLA and its non-toxic salts employed as a pharmaceutical for humans will range from about 1,000 parts per million (ppm) to
35 about 10,000 ppm of CLA of the human's diet. However, the upper limit of the amount to be employed is not

-14-

critical because CLA is relatively non-toxic and it is a normal constituent of the human diet (including human breast milk).

The preferred pharmaceutical and veterinary compositions of CLA contain the non-toxic sodium or potassium salt of CLA in combination with a pharmaceutical diluent. When the compositions are solutions or suspensions intended for oral administration the diluent will be one or more diluents, such as lactose or starch, and the product will be a tablet, capsule or liquid. When the compositions are solutions or suspensions intended for parenteral administration the preferred diluent will be Sterile Water for Injection U.S.P.

The amount of CLA to be added to an animal's feed as an additive can range from .01% to 2.0% or more by weight of the animal's or human's food.

It will be readily apparent to those skilled in the art that a number of modifications or changes may be made without departing from the spirit and scope of the present invention. Therefore, the invention is only to be limited by the claims.

-15-

The embodiments of the invention in which an exclusive property or privilege is claimed are the following:

1. A method of enhancing weight gain and feed efficiency in an animal which comprises administering to the animal a weight gain enhancing and feed efficiency enhancing amount of a conjugated linoleic acid.
2. A method of claim 1 in which the animal is a bird.
3. A method of claim 1 in which the animal is a mammal.
4. A method of increasing the efficiency of feed conversion in an animal which is capable of converting linoleic acid into CLA in situ, said method comprising administering to said animal a safe and effective amount of linoleic acid to increase the efficiency of feed conversion to body weight in said animal.
5
5. A method of improving the feed for an animal which comprises adding to said feed an amount of CLA which is effective to enhance weight gain and to increase the efficiency of feed conversion of said animal.
6. A feed of claim 5 in which the added amount of CLA is about 0.1% to about 2.0% of the weight of the feed.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/11093

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 31/20
US CL : 514/558,560

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/558,560

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

N/A

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-on-line
APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	O.H. Siegmund, et al, "THE MERCK VETERINARY MANUAL" published 1979 by Merck & Co. (NJ), see pages 1340-1343, 1374-1379.	1-6

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	"A"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

15 FEBRUARY 1994

Date of mailing of the international search report

MAR 22 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

KEVIN WEDDINGTON

Telephone No. (703) 308-1235